Precision Diabetes Management: Integrated East-West Approach
Construction of a Precision and Individualized Management Model for Diabetes With Integrated Traditional Chinese and Western Medicine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- The age at diabetes diagnosis is ≥18 years but <40 years.
Exclusion Criteria:
- The clinical diagnosis was type 1 diabetes, and at the time of enrollment, antibody levels or insulin/C-peptide results still supported the original diagnosis.
There were clear secondary factors contributing to hyperglycemia, such as Cushing's syndrome or pheochromocytoma.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Integrated Traditional Chinese and Western Medicine Management
|
No interventions
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Traditional Chinese Medicine Syndrome Score
Time Frame: Through study completion, an average of 3 months
|
Through study completion, an average of 3 months
|
|
HbA1c
Time Frame: Through study completion, an average of 3 months
|
Through study completion, an average of 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Triglycerides
Time Frame: Through study completion, an average of 3 months
|
Through study completion, an average of 3 months
|
|
High-Density Lipoprotein Cholesterol
Time Frame: Through study completion, an average of 3 months
|
Through study completion, an average of 3 months
|
|
Total Cholesterol
Time Frame: Through study completion, an average of 3 months
|
Through study completion, an average of 3 months
|
|
Fasting Blood Glucose
Time Frame: Through study completion, an average of 3 months
|
Through study completion, an average of 3 months
|
|
Low-Density Lipoprotein Cholesterol
Time Frame: Through study completion, an average of 3 months
|
Through study completion, an average of 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- CXZH2024059
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.